NASDAQ · SABS
SAB Biotherapeutics, Inc.
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
Loading market information…
AMEX · IGC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
IGC Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
IGC Pharma, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow IGC Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2025 |
|---|
| Jun 30, 2025 |
| -$0.020.0% vs estimate |
| $260.00K-14.75% vs estimate |
| Q3 2025 | Feb 18, 2025 | -$0.02+33.33% vs estimate | $257.00K+25.98% vs estimate |
|---|
| Q2 2025 | Nov 14, 2024 | -$0.02+33.33% vs estimate | $412.00K+41.58% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
$8.87-$0.19 (-2.1%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
$4.69+$0.17 (+3.76%)
AN2 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.77% below the high.
$6.64+$0.24 (+3.75%)
Nutriband Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.75% below the high.
$2.48-$0.02 (-0.8%)
Boundless Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.62% below the high.
$6.53+$0.19 (+2.92%)
NextCure, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.55% below the high.
$1.20-$0.03 (-2.44%)
Pluri Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.36% below the high.
$3.87-$0.13 (-3.25%)
Plus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.48% below the high.
